Disc Medicine Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Disc Medicine şirketinin toplam hissedar öz sermayesi $488.8M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $510.2M ve $21.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$500.95m
Eşitlik	US$488.83m
Toplam yükümlülükler	US$21.39m
Toplam varlıklar	US$510.22m

Son finansal sağlık güncellemeleri

Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans

Aug 13

Recent updates

Disc Medicine: Achieving Functional Endpoint More Important

Oct 06

Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans

Aug 13

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Jun 14

Disc Medicine: What's Behind The Huge Rally

Jan 31

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IRON 'nin kısa vadeli varlıkları ( $508.2M ) kısa vadeli yükümlülüklerini ( $20.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: IRON şirketinin kısa vadeli varlıkları ( $508.2M ) uzun vadeli yükümlülüklerini ( $1.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IRON borçsuzdur.

Borcun Azaltılması: IRON un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IRON şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: IRON, serbest nakit akışı her yıl % 36.6 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

Disc Medicine Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans

Recent updates

Disc Medicine, Inc. Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

Disc Medicine: Achieving Functional Endpoint More Important

Disc Medicine, Inc. Announces Appointment of Steve Caffé as Chief Regulatory Officer

Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans

Disc Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $177.984 million.

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Disc Medicine, Inc., Annual General Meeting, Jun 12, 2024

Independent Director notifies of intention to sell stock

Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria (EPP)

New major risk - Revenue and earnings growth

Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer

Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Key Executive notifies of intention to sell stock

Disc Medicine: What's Behind The Huge Rally

Key Executive notifies of intention to sell stock

Disc Medicine, Inc Announces Retirement of Brian MacDonald as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

Disc Medicine, Inc Announces Retirement of Brian MacDonald as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

Independent Director notifies of intention to sell stock

Disc Presents Initial Positive Data from Ongoing Phase 1B/2 Trial of Disc-0974 in Patients with Myelofibrosis (Mf) and Anemia At the 65Th American Society of Hematology (Ash) Annual Meeting

General Counsel notifies of intention to sell stock

General Counsel exercised options and sold US$176k worth of stock

General Counsel notifies of intention to sell stock

Disc Medicine Announces Departure of Joanne Bryce as Chief Financial Officer

Disc Medicine Announces Departure of Joanne Bryce as Chief Financial Officer

Disc Medicine, Inc. Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

Chief Financial Officer notifies of intention to sell stock

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia

Chief Financial Officer notifies of intention to sell stock

New minor risk - Share price stability

Disc Medicine, Inc. Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria at European Hematology Association (EHA) 2023 Congress

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria at European Hematology Association 2023 Congress

Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

No independent directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin